DrugPatentWatch Database Preview

Details for Patent: 8,754,109

« Back to Dashboard

Which drugs does patent 8,754,109 protect, and when does it expire?

Patent 8,754,109 protects ESBRIET and is included in two NDAs.

This patent has thirty-three patent family members in twenty-seven countries.

Summary for Patent: 8,754,109

Title:	Pirfenidone therapy and inducers of cytochrome P450
Abstract:	The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
Inventor(s):	Bradford; Williamson Z. (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee:	Intermune, Inc. (Brisbane, CA)
Application Number:	13/513,472
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,754,109

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Genentech Inc	ESBRIET	pirfenidone	CAPSULE;ORAL	022535-001	Oct 15, 2014		RX	Yes	Yes						METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-001	Jan 11, 2017		RX	Yes	No						ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-002	Jan 11, 2017		DISCN	Yes	No						ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-003	Jan 11, 2017		RX	Yes	Yes						ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY

Foreign Priority and PCT Information for Patent: 8,754,109

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	10250378	Mar 3, 2010
Canada	2710014	Oct 8, 2010

PCT Information
PCT Filed	December 03, 2010	PCT Application Number:	PCT/US2010/058936
PCT Publication Date:	June 09, 2011	PCT Publication Number:	WO2011/069089

Non-Orange Book US Patents Family Members for Patent 8,754,109

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,084,475	Pirfenidone therapy and inducers of cytochrome P450
8,648,098	Pirfenidone therapy and inducers of cytochrome P450

International Family Members for US Patent 8,754,109

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Taiwan	201315718
Taiwan	I440459
Taiwan	201121940
San Marino	T201200003